[Market Focus] Samchundang Pharm Surges Over 10% on Eylea Biosimilar Export News
Samchundang Pharm is experiencing a sharp rise following news of exports of its biosimilar for the ophthalmic disease treatment 'Eylea.'
As of 9:39 a.m. on June 5, Samchundang Pharm was trading at 159,900 won on the Korea Exchange, up 14,700 won (10.12%) from the previous day.
On this day, Samchundang Pharm announced that the first commercial shipment of its Eylea biosimilar had been shipped and that sales in the relevant country would begin in July.
Hot Picks Today
If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- RIA Accounts Surpass 240,000 Subscriptions... Sold Nvidia, Bought Samsung Electronics
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Manhole Cover Blasts Open in 12 Seconds... The Reason Behind the 'Gangnam Flood Disaster' [Report]"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!['WHO Declares International Public Health Emergency' Why the Untreatable 'Variant Ebola' Is More Deadly Than COVID-19 [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052110164072055_1779326201.png)
!["Please Help Us": How Much Do Those Bowing 90 Degrees These Days Actually Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
